6853-14-1

Usage

Classification

Psychoactive drug

Effects

Anxiolytic (reduces anxiety) and sedative (calming and relaxing)

Mechanism of action

GABA receptor agonist
Derived from the neurotransmitter gamma-aminobutyric acid (GABA)

Common uses

Dietary supplement, treatment of anxiety, insomnia, and various psychiatric disorders

Risks

Dependence and withdrawal symptoms
Use should be carefully monitored and limited to avoid potential adverse effects

Upstream product

• 96-09-3 styrene oxide 
• 124-40-3 dimethyl amine 
• 71-43-2 benzene 
• 3319-03-7 2-dimethylamino-1-phenyl-ethanone 
• 142282-74-4 2-iodo-2-phenylethanol 
• 50-00-0 formaldehyd 
• 7568-93-6 2-Amino-1-phenylethanol 
• 77184-09-9 N-(β-Hydroxyphenaethyl)-N-methyl-carbaminsaeure-(t-butyl)ester 
• 70-11-1 α-bromoacetophenone 
• 34469-10-8 (S)-2-(dimethylamino)-2-oxo-1-phenylethyl acetate 
• 56613-81-1 (S)-2-Amino-1-phenyl-1-ethanol 
• 51019-44-4 (S)-2-chloro-2-oxo-1-phenylethyl acetate 
• 7322-88-5 (S)-acetylmandelic acid 
• 17199-29-0 (S)-Mandelic acid 

Downstream Products

• 2202-68-8 (S)-2-dimethylamino-1-phenylethanol 
• 34469-09-5 (R)-2-dimethylamino-1-phenyl-ethanol 
• 66827-45-0 acetic acid-(2-dimethylamino-1-phenyl-ethyl ester) 
• 1557241-91-4 N,N-dimethyl-2-(4-nitro-1H- pyrazol-1-yl)-2-phenylethan-1-amine 
• 127677-23-0 Propionic acid (S)-2-dimethylamino-1-phenyl-ethyl ester 
• 1375799-72-6 (S)-2-(dimethylamino)-1-phenylethyl 6,6-dimethyl-3-(1-(trifluoromethyl)cyclobutanecarboxamido)-4,6 dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 
• 1375799-71-5 (S)-2-(dimethylamino)-1-phenylethyl 6,6-dimethyl-3-(1-(trifluoromethyl)cyclopropanecarboxamido)-4,6 dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 
• 1375799-69-1 (S)-2-(dimethylamino)-1-phenylethyl 6,6-dimethyl-3-(3,3,3-trifluoro-2,2-dimethylpropanamido)-4,6-dihydropyrrolo[3,4c]pyrazole-5(1H)-carboxylate- 
• 1041012-54-7 (S)-2-(dimethylamino)-1-phenylethyl 6,6 dimethyl-3-(tetrahydro-2H-pyran-2-carboxamido)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate- 
• 1041012-52-5 (S)-2-(dimethylamino)-1-phenylethyl 6,6-dimethyl-3-(tetrahydrofuran-2-carboxamido)-4,6-dihydropyrrolo[3,4-c]-pyrazole-5(1H)-carboxylate 
• 1041012-42-3 (S)-2-(dimethylamino)-1-phenylethyl 6,6-dimethyl-3-pivalamido-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 
• 1041012-33-2 (S)-2-(dimethylamino)-1-phenylethyl 6,6-dimethyl-3-(picolinamido)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 

Relevant academic research and scientific papers

An iron variant of the Noyori hydrogenation catalyst for the asymmetric transfer hydrogenation of ketones

We report the design of a new iron catalyst for the asymmetric transfer hydrogenation of ketones. This type of iron catalyst combines the structural characteristics of the Noyori hydrogenation catalyst (an axially chiral 2,2′-bis(phosphino)-1,1′-binaphthyl fragment and the metal-ligand bifunctional motif) and an ene(amido) group that can activate the iron center. After activation by 8 equivalents of potassiumtert-butoxide, (SA,RP,SS)-7aand (SA,RP,SS)-7bare active but nonenantioselective catalysts for the transfer hydrogenation of acetophenone and α,β-unsaturated aldehydes at room temperature in isopropanol. A maximum turnover number of 14480 was observed for (SA,RP,SS)-7ain the reduction of acetophenone. The right combination of the stereochemistry of the axially chiral 2,2′-bis(phosphino)-1,1′-binaphthyl group and the carbon-centered chiral amine-imine moiety in (SA,RP,RR)-7b′afforded an enantioselective catalyst for the preparation of chiral alcohols with moderate to good yields and a broad functional group tolerance.

waylen apperception HIV reverse transcriptase inhibitors in accordance with the law of the process for the asymmetric synthesis of one-pot synthesis (by machine translation)

The invention relates to a novel one pot method asymmetric synthesis process of a (S)-6-chlorine-4-cylopropyl ethylnen-4-trifluoromethyl-1,4-dihydro-2H-1,3-benzoxazine-2-ketone (Efavirenz) compound, the compound can be used as an reverse transcriptase inhibitor for human immunodeficiency virus (HIV). The invention also relates to a novel aminoalcohol ligand used for the process.

PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Provided herein are compounds of formula (AA): N N H HN O N N R R 6 A (R a ) p, (AA) stereoisomers or a pharmaceutically acceptable salt thereof, wherein A, R a, p, R and R 6 are defined herein, compositions including the compounds and methods of manufacturing and using the compounds for the treatment of diseases.

Discovery of pyrroloaminopyrazoles as novel PAK inhibitors

The P21-activated kinases (PAK) are emerging antitumor therapeutic targets. In this paper, we describe the discovery of potent PAK inhibitors guided by structure-based drug design. In addition, the efflux of the pyrrolopyrazole series was effectively reduced by applying multiple medicinal chemistry strategies, leading to a series of PAK inhibitors that are orally active in inhibiting tumor growth in vivo.

Enantioselective reduction of α-substituted ketones mediated by the boronate ester TarB-NO2

A facile and mild reduction procedure is reported for the preparation of chiral secondary alcohols prepared from α-substituted ketones using sodium borohydride and the chiral boronate ester (l)-TarB-NO2. Direct reduction of substituted ketones bearing Lewis basic heteroatoms generally provided secondary alcohols of only modest enantiomeric excess likely due to either competition between the target carbonyl and the functionalized sidechains at the Lewis acidic boron atom in TarB-NO2 or the added steric bulk of the α-sidechain. As an alternative method, these substrates were synthesized using TarB-NO2 via a two-step procedure involving the reduction of an α-halo ketone to a chiral terminal epoxide, followed by regioselective/regiospecific epoxide opening by various nucleophiles. This procedure provides access to a variety of functionalized secondary alcohols including β-hydroxy ethers, thioethers, nitriles, and amines with enantiomeric excesses of 94% and yields up to 98%.

CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS

Carbonylamino Pyrrolopyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.

Ruthenium-catalyzed /V-alkylation of amines and sulfonamides using borrowing hydrogen methodology

The alkylation of amines by alcohols has been achieved using 0.5 mol percent [Ru(p-cymene)CI2]2 with the bidentate phosphines dppf or DPEphos as the catalyst. Primary amines have been converted into secondary amines, and secondary amines into tertiary amines, including the syntheses of Piribedil, Tripelennamine, and Chlorpheniramine. A/-Heterocyclization reactions of primary amines are reported, as well as alkylation reactions of primary sulfonamides. Secondary alcohols requiremore forcing conditions than primary alcohols but are still effective a lkylating agents in the presence of this catalyst.

Catalytic asymmetric borane reduction of prochiral ketones by using (S)-2-(anilinomethyl)pyrrolidine

Catalytic asymmetric borane reduction of prochiral ketones was examined in the presence of (S)-2-(anilinornethyl)pyrrolidine. Chiral secondary alcohols were obtained with moderate to high enantiomeric excesses (up to 96% ee).

Stereoselective Method for the Production of Clopidogrel

The present invention relates to processes for preparing a compound of the general formula (Ia) wherein X is a halogen atom, or a pharmaceutically acceptable salt thereof, wherein a compound of the formula (II) wherein X is as defined above and Y and Z independently represent a leaving group each, is reacted with an optically active amino alcohol to form a first mixture of diastereomers.

Highly enantioselective synthesis of β-amino alcohols

N,N-Dialkyl-β-amino alcohols derived from α-amino acids can be rearranged enantiospecifically by using TFAA/Et3N/NaOH to give 1,2-amino alcohols with enantiomeric excess up to 99%.